Who
Jacquelyn L. Sumer
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Cullinan Therapeutics; Chief Legal & Compliance Off, Genocea Biosciences.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $339K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Mar 2021
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $21K2,470 at $8.60 | filing |
| 30 Jun 2026filed 2 Jul 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $21K2,470 at $8.60 | filing |
| 24 Feb 2026filed 25 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K3,601 at $14.47 | filing |
| 24 Feb 2026filed 25 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K3,601 at $14.47 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K3,742 at $13.62 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K3,742 at $13.62 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K3,480 at $9.67 | filing |
| 25 Feb 2025filed 27 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K3,756 at $8.53 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K3,482 at $11.41 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 21 Dec 2023filed 22 Dec 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K1,400 at $8.50 | filing |
| 18 Dec 2023filed 20 Dec 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,384290 at $8.22 | filing |
| 20 Jun 2023filed 21 Jun 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,766291 at $12.94 | filing |
| 18 May 2023filed 19 May 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,549291 at $8.76 | filing |
| 18 Apr 2023filed 20 Apr 2023 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,106290 at $10.71 | filing |
News
No headline names them, or the companies they trade most, lately.